Dose selection and pharmacokinetics of montelukast (sprinkles) in >=6 month to <2 year old asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002
Influence of an incentive spacer on adherence to prescribed treatment in 2-6 year old children over a 3 month period Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007
Efficacy of montelukast in patients aged 2 to 5 years with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
Formoterol in acute asthma in children 6-14 years old Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003
The effect of single dose inhaled budesonide on Amppc20 in patients with mild asthma: a 3 month follow up Source: Eur Respir J 2005; 26: Suppl. 49, 369s Year: 2005
Low dose inhaled fluticasone propionate compared with montelukast in children 6-12 years old Source: Eur Respir J 2003; 22: Suppl. 45, 535s Year: 2003
A comparison of nebulized budesonide, intramuscular and oral dexamethasone in the treatment of croup among children aged 6-36 months Source: Eur Respir J 2003; 22: Suppl. 45, 284s Year: 2003
Exercise induced dyspnea among 12-13 year old children Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation Year: 2012
Bupropion hydrochloride sustained release (SR) is an effective and well tolerated aid to smoking cessation in smokers with cardiovascular disease. 12 month follow-up phase data (ZYB40014) Source: Eur Respir J 2002; 20: Suppl. 38, 611s Year: 2002
Which method is effective in patient with asthma to guide the treatment? (2 year follow-up study) Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
The effectiveness of carrying out 6 month and 1 year re-assessments for respiratory patients post pulmonary rehabilitation Source: Annual Congress 2012 - Physiotherapy and rehabilitation strategies in respiratory diseases and beyond Year: 2012
Montelukast vs. fluticasone in patients aged 6 to 14 with mild persistent asthma: the MOSAIC study Source: Eur Respir J 2004; 24: Suppl. 48, 377s Year: 2004
The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Salmeterol 50μg b.i.d. significantly increases though fev1 in COPD up to 12 months without loss of effect Source: Eur Respir J 2003; 22: Suppl. 45, 376s Year: 2003
Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001
Paracetamol use in infancy and risk of asthma in 6 to 7 year old children – ISAAC phase three Source: Annual Congress 2008 - Asthma epidemiology Year: 2008
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting2 -agonists (LABA) in moderately severe COPD Source: Annual Congress 2011 - Disease management in specific primary care populations Year: 2011
Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients Source: Annual Congress 2010 - Bronchodilators in airways disease Year: 2010
The efficiency of Langerhans‘ cell hystioctosis treatment (3 years follow-up) Source: Annual Congress 2011 - Rare diffuse lung diseases Year: 2011
Pulmonary thromboembolism in HIV (+) patients under 50 years old: a six year study Source: Annual Congress 2007 - Venous thromboembolic disease Year: 2007